Notice: This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BOLD vs. ACRV, RIGL, AMRN, OMER, ENTA, TSVT, NKTX, EPIX, PEPG, and NKTRShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include Acrivon Therapeutics (ACRV), Rigel Pharmaceuticals (RIGL), Amarin (AMRN), Omeros (OMER), Enanta Pharmaceuticals (ENTA), 2seventy bio (TSVT), Nkarta (NKTX), ESSA Pharma (EPIX), PepGen (PEPG), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. Acrivon Therapeutics Rigel Pharmaceuticals Amarin Omeros Enanta Pharmaceuticals 2seventy bio Nkarta ESSA Pharma PepGen Nektar Therapeutics Acrivon Therapeutics (NASDAQ:ACRV) and Audentes Therapeutics (NASDAQ:BOLD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Does the media favor ACRV or BOLD? In the previous week, Acrivon Therapeutics had 4 more articles in the media than Audentes Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 0 mentions for Audentes Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.96 beat Audentes Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Acrivon Therapeutics Positive Audentes Therapeutics Neutral Do analysts recommend ACRV or BOLD? Acrivon Therapeutics presently has a consensus target price of $23.83, suggesting a potential upside of 197.54%. Audentes Therapeutics has a consensus target price of $23.00, suggesting a potential upside of 671.81%. Given Audentes Therapeutics' higher probable upside, analysts plainly believe Audentes Therapeutics is more favorable than Acrivon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Audentes Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in ACRV or BOLD? 71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 5.3% of Audentes Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings & valuation, ACRV or BOLD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$60.39M-$2.77-2.89Audentes TherapeuticsN/AN/A-$49.43MN/AN/A Does the MarketBeat Community prefer ACRV or BOLD? Audentes Therapeutics received 439 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.88% of users gave Acrivon Therapeutics an outperform vote while only 69.22% of users gave Audentes Therapeutics an outperform vote. CompanyUnderperformOutperformAcrivon TherapeuticsOutperform Votes3196.88% Underperform Votes13.13%Audentes TherapeuticsOutperform Votes47069.22% Underperform Votes20930.78% Is ACRV or BOLD more profitable? Audentes Therapeutics' return on equity of 0.00% beat Acrivon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -47.31% -43.10% Audentes Therapeutics N/A N/A N/A SummaryAcrivon Therapeutics beats Audentes Therapeutics on 6 of the 11 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.31M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / BookN/A5.324.665.02Net Income-$49.43M$153.56M$119.06M$225.46M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes Therapeutics2.008 of 5 stars$2.98+2.1%$23.00+671.8%N/A$66.31MN/A0.00207ACRVAcrivon Therapeutics3.423 of 5 stars$8.35+1.0%$23.83+185.4%+57.7%$257.82MN/A-3.0158Short Interest ↓Positive NewsRIGLRigel Pharmaceuticals2.2611 of 5 stars$14.27-0.5%$31.13+118.1%+78.1%$250.55M$130.30M-16.59147Upcoming EarningsAMRNAmarin0.3866 of 5 stars$0.60-1.6%N/A-16.0%$247.31M$264.78M-7.53360News CoverageOMEROmeros0.6943 of 5 stars$4.22-1.6%N/A+261.1%$244.54MN/A-1.80198ENTAEnanta Pharmaceuticals3.9721 of 5 stars$11.49-0.1%$20.00+74.1%+22.6%$243.35M$71.96M-2.11145Short Interest ↑TSVT2seventy bio1.7848 of 5 stars$4.58-4.8%$9.00+96.5%+88.8%$235.87M$100.39M-1.49440NKTXNkarta2.5503 of 5 stars$3.33-2.3%$17.50+425.5%+67.0%$234.96MN/A-1.66140EPIXESSA Pharma2.2823 of 5 stars$5.28-2.4%$16.50+212.5%-71.2%$234.24MN/A-8.5250News CoverageGap DownPEPGPepGen2.5314 of 5 stars$7.07-2.9%$19.33+173.5%+27.1%$230.41MN/A-2.1472NKTRNektar Therapeutics4.2982 of 5 stars$1.25-1.6%$2.33+86.7%+153.6%$230.03M$93.16M-1.39220Upcoming EarningsNews Coverage Related Companies and Tools Related Companies Acrivon Therapeutics Competitors Rigel Pharmaceuticals Competitors Amarin Competitors Omeros Competitors Enanta Pharmaceuticals Competitors 2seventy bio Competitors Nkarta Competitors ESSA Pharma Competitors PepGen Competitors Nektar Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
